Acro Biomedical Co., Ltd. (ACBM)
USD 0.0
(0.0%)
USD 0.0
(0.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | -15.86 Million USD | -106.27% |
| 2021 | -7.69 Million USD | -5797.13% |
| 2020 | -130.46 Thousand USD | 69.14% |
| 2019 | -422.75 Thousand USD | -182.0% |
| 2018 | 515.55 Thousand USD | 23033.72% |
| 2017 | -2248.00 USD | 94.82% |
| 2016 | -43.42 Thousand USD | 8.55% |
| 2015 | -47.49 Thousand USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 Q1 | -4 Million USD | -1.77% |
| 2023 Q2 | -3.19 Million USD | 20.2% |
| 2022 FY | -15.86 Million USD | -106.27% |
| 2022 Q2 | -3.99 Million USD | -1.73% |
| 2022 Q3 | -4.01 Million USD | -0.36% |
| 2022 Q1 | -3.92 Million USD | -1.97% |
| 2022 Q4 | -3.93 Million USD | 1.92% |
| 2021 Q1 | -56.99 Thousand USD | 26.66% |
| 2021 Q2 | -793.32 Thousand USD | -1292.01% |
| 2021 Q3 | -2.99 Million USD | -276.98% |
| 2021 Q4 | -3.85 Million USD | -28.82% |
| 2021 FY | -7.69 Million USD | -5797.13% |
| 2020 Q3 | -71.54 Thousand USD | -13.97% |
| 2020 Q1 | 81.55 Thousand USD | 208.12% |
| 2020 FY | -130.46 Thousand USD | 69.14% |
| 2020 Q4 | -77.7 Thousand USD | -8.62% |
| 2020 Q2 | -62.77 Thousand USD | -176.97% |
| 2019 Q3 | -64.46 Thousand USD | 5.33% |
| 2019 Q1 | -214.76 Thousand USD | -127.9% |
| 2019 FY | -422.75 Thousand USD | -182.0% |
| 2019 Q4 | -75.43 Thousand USD | -17.02% |
| 2019 Q2 | -68.09 Thousand USD | 68.29% |
| 2018 Q4 | -94.23 Thousand USD | -158.5% |
| 2018 FY | 515.55 Thousand USD | 23033.72% |
| 2018 Q3 | 161.08 Thousand USD | -8.59% |
| 2018 Q2 | 176.22 Thousand USD | 79.8% |
| 2018 Q1 | 98.01 Thousand USD | 22.17% |
| 2017 FY | -2248.00 USD | 94.82% |
| 2017 Q1 | -22.44 Thousand USD | -202.75% |
| 2017 Q2 | -11.88 Thousand USD | 47.03% |
| 2017 Q3 | 39.49 Thousand USD | 432.25% |
| 2017 Q4 | 80.22 Thousand USD | 103.13% |
| 2016 FY | -43.42 Thousand USD | 8.55% |
| 2016 Q4 | -7413.00 USD | -20.99% |
| 2016 Q3 | -6127.00 USD | 64.22% |
| 2016 Q2 | -17.12 Thousand USD | -169.69% |
| 2016 Q1 | -6350.00 USD | 54.07% |
| 2015 Q4 | -13.82 Thousand USD | -491.61% |
| 2015 Q2 | -18.00 USD | 37.93% |
| 2015 Q1 | -29.00 USD | 99.94% |
| 2015 FY | -47.49 Thousand USD | 0.0% |
| 2015 Q3 | -2337.00 USD | -12883.33% |
| 2014 Q4 | -45.1 Thousand USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | -1.33 Million USD | -1088.361% |
| Arch Therapeutics, Inc. | -5.04 Million USD | -214.596% |
| Evofem Biosciences, Inc. | -17.84 Million USD | 11.079% |
| Nascent Biotech, Inc. | -2.22 Million USD | -611.686% |
| Rebus Holdings, Inc. | -664 Thousand USD | -2290.021% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 119.388% |
| Qrons Inc. | -643.67 Thousand USD | -2365.481% |
| Adynxx, Inc. | - USD | Infinity% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -3973.655% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 71.41% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -3719.624% |
| Skye Bioscience, Inc. | -13.67 Million USD | -16.076% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 77.893% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 422.896% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -5963.493% |
| SQZ Biotechnologies Company | -75.82 Million USD | 79.071% |
| Intellipharmaceutics International Inc. | -2.85 Million USD | -456.734% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -933.153% |
| Mesoblast Limited | -84.14 Million USD | 81.14% |
| Marizyme, Inc. | -34.08 Million USD | 53.443% |
| Genus plc | 6.4 Million USD | 347.965% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 262.893% |
| Pharming Group N.V. | -4.87 Million USD | -225.23% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -698.888% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -1603.895% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | -90.057% |
| ContraFect Corporation | -56.88 Million USD | 72.104% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | -248.424% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -1031.943% |
| IMV Inc. | -38.67 Million USD | 58.963% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -476.905% |
| MultiCell Technologies, Inc. | -722.81 USD | -2195461.351% |
| ONE Bio Corp. | 13.68 Million USD | 215.994% |
| Accustem Sciences Inc. | -3.74 Million USD | -323.597% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 73.098% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -3185.238% |
| Q BioMed Inc. | -3.44 Million USD | -360.578% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 548.298% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -503.981% |
| Biomind Labs Inc. | -1 Million USD | -1471.879% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 71.131% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | -446.997% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | -138.714% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -751.212% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -52883.898% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -721.156% |
| GB Sciences, Inc. | -1.42 Million USD | -1017.187% |
| Alpha Cognition Inc. | -9.7 Million USD | -63.511% |
| HST Global, Inc. | -140.9 Thousand USD | -11162.561% |
| CSL Limited | 3.7 Billion USD | 100.429% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -1310.761% |
| Halberd Corporation | -75.05 Thousand USD | -21045.552% |
| Enzolytics Inc. | -2.14 Million USD | -638.54% |
| Agentix Corp. | -1.37 Million USD | -1056.892% |
| Resverlogix Corp. | -12.74 Million USD | -24.478% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | -400.895% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 96.266% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -1420.09% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | -443.588% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -904.824% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | -366.074% |
| AVAX Technologies, Inc. | 6.69 Million USD | 337.114% |
| Zenith Capital Corp. | -8.94 Million USD | -77.454% |
| Genscript Biotech Corporation | -415.79 Million USD | 96.183% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -90995.442% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -546.342% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -9152.976% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -691.604% |
| Kadimastem Ltd | -3.04 Million USD | -421.988% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -1512.691% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -1163.514% |
| BioStem Technologies, Inc. | -7.77 Million USD | -104.008% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -8644.379% |
| LadRx Corporation | -3.82 Million USD | -315.044% |
| Cell Source, Inc. | -4.32 Million USD | -266.901% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2210.174% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -2210.174% |
| NovAccess Global Inc. | -2.46 Million USD | -543.343% |
| Affymax, Inc. | -15.04 Million USD | -5.475% |
| Itoco Inc. | -919.14 Thousand USD | -1626.585% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | -274.426% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -1318.207% |
| Mobile Lads Corp. | -554.55 Thousand USD | -2761.732% |
| CytoDyn Inc. | -18.05 Million USD | 12.118% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -62950.207% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -7110.96% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -2710.181% |
| SYBLEU INC | -149.18 Thousand USD | -10537.979% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -773.73% |
| International Stem Cell Corporation | -663 Thousand USD | -2293.625% |
| Bioxytran, Inc. | -3.82 Million USD | -315.422% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -30047.677% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -77922.306% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 56.241% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -880.824% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -2056.698% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | -410.117% |
| Neutra Corp. | -229.48 Thousand USD | -6815.34% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 9.517% |
| PureTech Health plc | -146.19 Million USD | 89.145% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 26.157% |
| IXICO plc | -1.43 Million USD | -1004.366% |
| IntelGenx Technologies Corp. | -9.49 Million USD | -67.208% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 86.971% |
| CSL Limited | 3.81 Billion USD | 100.416% |
| Cellectis S.A. | -108.85 Million USD | 85.422% |